Stock Fundamentals

Company Information

▼
Company Name
Immunome Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US45257U1088
CIK: 0001472012
CUSIP: 45257U108
Currency: USD
Full Time Employees: 168
Phone: 425 939 7410
Website: https://immunome.com
Fiscal Year End: December
IPO Date: Oct 02, 2020
Description:

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Address:

18702 North Creek Parkway, Bothell, WA, United States, 98011

Directors & Officers

▼
Name Title Year Born
Dr. Clay B. Siegall Ph.D. Chairman, President & CEO 1961
Ms. Sandra G. Stoneman Esq., J.D. Chief Legal Officer, General Counsel & Corporate Secretary 1973
Mr. Kinney Horn Chief Business Officer 1975
Mr. Max Rosett Chief Financial Officer 1990
Dr. Philip Tsai Chief Technical Officer NA
Dr. Jack Higgins Ph.D. Chief Scientific Officer 1980
Dr. Robert J. Lechleider M.D. Chief Medical Officer 1962
Mr. Roee Shahar Executive Vice President of Commercial NA

Institutional Holders

▼
Holder Name Shares Date Reported % Out Value % Change
FMR Inc 16.55M Dec 31, 2025 15.00% $0.02 26.75%
T. Rowe Price Investment Management,Inc. 8.42M Sep 30, 2025 7.63% $0.06 1.73%
Vanguard Group Inc 6.04M Dec 31, 2025 5.47% $0.00 23.39%
BlackRock Inc 5.82M Sep 30, 2025 5.28% $0.00 0.90%
Redmile Group, LLC 5.02M Sep 30, 2025 4.55% $5.72 3.10%
Point72 Asset Management, L.P. 4.82M Sep 30, 2025 4.37% $0.09 2.96%
Enavate Sciences GP, LLC 4.77M Sep 30, 2025 4.32% $17.05 0.00%
PRIMECAP Management Company 4.69M Dec 31, 2025 4.25% $0.08 55.25%
T. Rowe Price Associates, Inc. 3.74M Sep 30, 2025 3.39% $0.00 25.51%
Driehaus Capital Management LLC 3.71M Dec 31, 2025 3.36% $0.54 432.05%
EcoR1 Capital, LLC 2.86M Dec 31, 2025 2.59% $2.78 -30.00%
State Street Corp 2.80M Sep 30, 2025 2.54% $0.00 11.23%
Jefferies Financial Group Inc 2.10M Sep 30, 2025 1.90% $0.12 0.69%
Geode Capital Management, LLC 1.89M Sep 30, 2025 1.72% $0.00 1.83%
Morgan Stanley - Brokerage Accounts 1.83M Sep 30, 2025 1.66% $0.00 353.51%
Sofinnova Ventures 1.62M Dec 31, 2025 1.47% $1.50 271.17%
Woodline Partners LP 1.58M Dec 31, 2025 1.43% $0.13 23.59%
Balyasny Asset Management LLC 1.43M Dec 31, 2025 1.30% $0.04 0.00%
Readystate Asset Management LP 1.32M Sep 30, 2025 1.19% $0.66 -2.61%
SILVERARC CAPITAL MANAGEMENT, LLC 1.13M Dec 31, 2025 1.02% $3.36 0.00%

Shares Statistics

▼
Shares Outstanding: 110.34M
Shares Float: 76.02M
% Insiders: 786.80%
% Institutions: 10,533.10%
Short % Float: 15.05%

🏆 Top 10 Institutional Holders

▼
Rank Holder Name Shares Held % of Shares Change Date Reported
1 FMR Inc 16.55M 15.00% ▲ 26.75% Dec 31, 2025
2 T. Rowe Price Investment Management,Inc. 8.42M 7.63% ▲ 1.73% Sep 30, 2025
3 Vanguard Group Inc 6.04M 5.47% ▲ 23.39% Dec 31, 2025
4 BlackRock Inc 5.82M 5.28% ▲ 0.90% Sep 30, 2025
5 Redmile Group, LLC 5.02M 4.55% ▲ 3.10% Sep 30, 2025
6 Point72 Asset Management, L.P. 4.82M 4.37% ▲ 2.96% Sep 30, 2025
7 Enavate Sciences GP, LLC 4.77M 4.32% ▲ 0.00% Sep 30, 2025
8 PRIMECAP Management Company 4.69M 4.25% ▲ 55.25% Dec 31, 2025
9 T. Rowe Price Associates, Inc. 3.74M 3.39% ▲ 25.51% Sep 30, 2025
10 Driehaus Capital Management LLC 3.71M 3.36% ▲ 432.05% Dec 31, 2025

Valuation Metrics

▼
Enterprise Value: $2.14B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $2.41B
EBITDA: $-204.56M
Book Value: $2.88
Earnings/Share: $-2.96
Profit Margin: 0.00%
Operating Margin: -2,137.10%
ROA (TTM): -46.48%
ROE (TTM): -93.04%
Revenue (TTM): $9.68M
Revenue/Share (TTM): $0.12
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 69.80%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios (Yearly)

▼

Financial Ratios (Quarterly)

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 4.08x 0.00x 0.25x N/A 0.00x
2023-12-31 6.63x 0.00x 0.19x N/A -0.01x
2022-12-31 3.09x 0.01x 0.31x -7,380.20x -0.01x
2021-12-31 5.82x 0.01x 0.17x -2,520.40x -0.01x
2020-12-31 14.12x 0.01x 0.07x -322.66x -0.05x
2019-12-31 1.88x -0.02x 8.04x -97.62x -0.06x
2018-12-31 1.35x -0.04x 6.67x -54.91x -0.13x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 30, 2025 Clay B Siegall N/A Purchase 4.73K $21.15 $100.02K
Dec 22, 2025 Isaac Barchas N/A Sale 383.20K $21.74 $8.33M
Dec 19, 2025 Clay B Siegall N/A Purchase 7.28K $20.48 $149.05K
Dec 19, 2025 Philip Tsai N/A Purchase 10.00K $20.49 $204.90K
Dec 18, 2025 Clay B Siegall N/A Purchase 46.51K $21.50 $999.99K
Jun 03, 2025 Jean Jacques Bienaime N/A Purchase 5.00K $9.38 $46.90K
Mar 26, 2025 Clay B Siegall N/A Purchase 137.10K $7.29 $999.46K
Mar 24, 2025 Jean Jacques Bienaime N/A Purchase 7.00K $8.21 $57.47K
Mar 24, 2025 Philip Tsai N/A Purchase 12.30K $8.42 $103.57K

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMNM.US!